**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a case series, 4 patients (3 men and 1 woman) aged 53−74 years were described, who developed Coronavirus disease 2019 (COVID-19) during treatment with azathioprine, ciclosporin, mesalazine, mycophenolate mofetil, prednisone or tacrolimus \[*routes, dosages and durations of treatments to reactions onset not stated; not all outcomes stated*\].

Case 1: This report describes a 54-year-old man, who developed COVID-19 during treatment with tacrolimus and mycophenolate mofetil. The man with end-stage renal disease of unknown aetiology, underwent deceased donor renal transplantation 20 years previously. His course was complicated by transplant glomerulopathy with stage III chronic kidney disease and baseline serum creatinine of 1.9 mg/dL. His maintenance immunosuppressive medications included mycophenolate mofetil and tacrolimus. Additionally, his medical history was significant for hypertension and insulin-dependent diabetes mellitus; he had been receiving losartan. He had recent health-care contacts and was residing in an area with local SARS-CoV-2 transmission, but did not have any known direct contact with a case. His initial symptoms were insidious in onset and consisted of malaise, nausea, fever, chills, vomiting, dyspnoea, diarrhea and dry cough. One day after the start of symptoms, he was observed in a walk-in clinic, where chest X-ray and influenza testing were negative. His symptoms continued, and after 3 days with no resolution of fever, he was referred to an emergency department. On admission, he was febrile, with normal BP and heart rate. Oxygen saturation was found to be 93% on ambient air. Exam was remarkable for increased work of breathing and mild tachypnoea with clear lungs on auscultation. Initial laboratory studies showed a normal WBC count and differential acute-on-chronic kidney injury. A chest X-ray revealed a subtle consolidation in the left mid-lung. Nasopharyngeal swab real-time polymerase chain reaction (RT-PCR) testing was found to be positive for SARS-CoV-2 RNA. A diagnosis of COVID-19 was considered. To improve immune function, mycophenolate mofetil was interrupted on admission, and on the basis of worsened renal function, tacrolimus dose was decreased. His tacrolimus level reduced to 2.8 ng/mL prior to re-commencing the medication. On day 8 of admission, prednisone was added to his immunosuppression regimen to provide further immunosuppression in the setting of the reducing tacrolimus level. His losartan was interrupted on admission because of acute kidney injury, which was ascribed to volume depletion from decreased oral intake, vomiting and diarrhoea. Empiric azithromycin and ceftriaxone were administered for community acquired pneumonia, although concomitant bacterial superinfection or infection ultimately were not suspected. The severity of his symptoms peaked on day 5 of admission and illness on day 8 of admission. His oxygen saturation reduced to 88% on 2 L/min nasal cannula. He needed a maximum supplemental oxygen support of 4 L/min via nasal cannula. A repeat chest X-ray revealed interval development of bilateral patchy consolidations. On the basis of a hypothesised antiviral effect, he was initiated on off-label treatment with chloroquine 500mg two times a day. This therapy was changed on day 8 of admission to off-label hydroxychloroquine 400mg two times on the first day followed by 200mg two times a day for 4 days. By day 12 of admission, he had normal oxygenation on ambient air. On hospital day 13, he was discharged home and advised to practice self-quarantine until 72 hours following resolution of all the symptoms and clearance by his transplant physician. Prednisone and tacrolimus were continued. Losartan and mycophenolate mofetil were not re-commenced at discharge. Repeat qualitative nasopharyngeal RT-PCR performed for SARS-CoV-2 was found to be positive on the day of discharge (16 days following symptom onset), but became negative on days 22 and 39 following symptom onset.

Case 2: This report describes a 67-year-old man, who developed COVID-19 during treatment with ciclosporin. The man underwent deceased donor liver transplantation for cirrhosis because of hepatitis C infection 19 years earlier. His maintenance immunosuppressive consisted of ciclosporin monotherapy. He sustained a pelvic fracture because of a ground-level fall and was residing in a subacute care facility, which was affected by COVID-19 outbreak. His wife was also found to be positive for SARS-CoV-2. On presentation to the emergency department, he reported several days of subjective fever, dry cough, increased confusion, fatigue and increased frequency of loose bowel movements from a baseline of two bowel movements daily with lactulose up to 5 bowel movements daily. He was afebrile, and his oxygen saturation was found to be 92% on ambient air. Examination was remarkable for occasional wheezing. Laboratory studies showed leucopenia, mild acute kidney injury and lymphopenia. Nasopharyngeal swab real-time polymerase chain reaction testing was found to be positive for SARS-CoV-2 RNA. A diagnosis of COVID-19 was considered. He was initially admitted to the ICU because of hypotension, which resolved in less than 24 hours with hydration. His acute kidney injury also resolved with hydration. He needed a maximal supplemental oxygen of 2 L/min via nasal cannula. His ciclosporin was continued without adjustment. The respiratory symptoms remained mild, and after 6 days, he was discharged home. He was contacted 12 days following admission and he reported feeling normal.

Case 3: This report describes a 53-year-old woman, who developed COVID-19 during treatment with ciclosporin, azathioprine and prednisone. The woman underwent bilateral lung transplantation 20 years previously due to chronic obstructive pulmonary disease. She also had various other comorbidities including a history of end-stage renal disease because of calcineurin inhibitor toxicity. At the time, her immunosuppressive medications included prednisone, ciclosporin and azathioprine. She had contact with a family member visiting from another state, who was advised to self-quarantine for suspected COVID-19 infection. For a routine visit, she presented to the lung transplant clinic. She reported fatigue, mild increased dyspnoea for 4−5 days and a mild non-productive cough. She was afebrile in the clinic with a normal BP and heart rate. Her oxygen saturation was found to be 98% on ambient air. Examination was significant for mild deterioration of baseline global weakness and baseline low body mass index. Laboratory studies showed leucopenia and slightly aggravated lymphopenia. Real-time polymerase chain reaction identified SARS-CoV-2 RNA in a nasopharyngeal swab sample. A confirmatory testing of the same sample was also found to be positive, and she was diagnosed with COVID-19. Following her clinic visit, she returned home and was advised to self-quarantine. The immunosuppressive medications were not altered. Five days after visiting the clinic, she experienced an increase in dyspnoea and cough. These symptoms ameliorated the following day with increased volume removal by peritoneal dialysis. She developed no fevers. Nine days after visiting the clinic, her dyspnoea and cough had improved. She was otherwise at her baseline health.

Case 4: This report describes a 74-year-old man, who developed COVID-19 during treatment with tacrolimus and mesalazine. The man underwent heart transplantation 23 years earlier. He also had various other comorbidities with a significant medical history including ulcerative colitis and cerebrovascular accident being treated with warfarin. He had been receiving mesalazine for ulcerative colitis, along with tacrolimus for maintenance immunosuppression. In the weeks before disease onset, he visited a local coffee shop and grocery store sporadically, but was otherwise living alone and relatively isolated. He first noticed a high fever, which was measured at home. At a clinic visit the following day, he experienced no sore throat, rhinorrhea, cough, shortness of breath, diarrhoea or nausea. At the time of assessment, he was afebrile. Oxygen saturation at rest was found to be 95% on ambient air. Exam showed faint rales at the R lung base. A chest X-ray showed a stable elevation of the left hemidiaphragm with no new abnormality. Nasopharyngeal swab real-time polymerase chain reaction testing was found to be positive for SARS-CoV-2 RNA. A diagnosis of COVID-19 was considered. Following his clinic visit, he returned home and was advised to self-quarantine. Two days after visiting the clinic, he reported persisting intermittent fevers along with chills, new mild sore throat and a new mild dry cough, but no shortness of breath. Seven days after visiting the clinic, his fevers had resolved. Eleven days following presentation, all his symptoms resolved.
